Abstract
Serum prostate specific antigen (PSA) has been used as an accurate means of detecting and monitoring prostate cancer. An analysis of PSA levels, digital rectal examination and bone scan findings was carried out in a group of patients with a view to determine whether PSA can accurately predict bone metastases in carcinoma prostate and its correlation with digital examination and bone metastasis status. In 32 case series, 30 cases on followed-up after treatment of the primary, 2 of total 32 cases received hormonal therapy. one out of three with normal PSA had bone metastases. In 25 cases with positive bone scans, 23 had elevated PSA levels (mean 79.9 ng /ml). In an untreated patient with elevated PSA, a bone scan may be required to exclude bone metastases, whereas during follow-up after treatment, a normal PSA level may obviate a “routine” bone scan.
Keywords: Serum prostate specific antigen (PSA), adenocarcinoma prostate, bone scintigraphy, hormonal therapy, metastases.
References
- LANGE, P H, ERCOLE, C J, LIGHTNER, D J ET AL, The value of serum prostate specific antigen determination before and after radical prostatectomy, /. , 141, 873-879 (1989).
- STAMEY, T A, KABALIN, J N, McNEAL, J E ET AL, Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients, /. , 141, 1076-1083 (1989).
- STAMEY, T A, YANG, N, HAY, A R ET AL, Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate, New Engl. J. Med., 317, 909-916 (1987).
- FERRO, M A, BARNES, I, ROBERTS, J M and SMITH, P J, Tumour markers in prostatic carcinoma. A comparison of prostate specific antigen with acid phosphatase, J. Urol., 60, 69-71 (1987).
- TERRIS, M K, KLONECKE, A S, McDOUGALL, I R and STAMEY, T A, Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy, Nucl. Med., 32, 1713-1717 (1991).
- LEO, M E, BILHARTZ, D L, BERGSTRALH, E J and OESTERLING, J E, Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? /. , 145, 802-806 (1991)
- CHYBOWSKI, F M, KELLER, J J L, BERGSTRALH, E J and OESTERLING, J E, Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: prostate specific antigen is superior to allother clinical parameters, /. Urol., 145, 313-318 (1991)
Corresponding Author
Dr B Revanth Kumar
Resident in Dept of Surgery, Kempegowda Institute of Medical Sciences and Research Centre K.R Road,
VV Puram Bangalore Pin:560004 INDIA
Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Ph:+918885114182
DOI: https://dx.doi.org/10.18535/jmscr/v5i10.146
